Rare disease drugs cost up to $2.1M per patient, sparking affordability crisis

A child with spinal muscular atrophy needs a drug called Spinraza. The first year of treatment costs €420,000. The next year, and every year after, it costs €210,000. In the United States, a competing treatment called Zolgensma carries a price tag of $2.1 million per patient—a single dose, a single life. These are not hypothetical numbers. They are the actual asking prices for medications that can mean the difference between walking and paralysis, between remission and death.

Spain's consumer advocacy organization, the OCU, has begun documenting these prices and asking a straightforward question: at what point does medicine become a luxury good available only to the wealthy? The answer, they argue, is now. Kymriah, used to treat acute lymphoblastic leukemia, costs €320,000 per patient. Yescarta, for certain lymphomas, costs €327,000. The pattern is unmistakable, and the consequences are concrete. Patients cannot access treatments their doctors know could save them. Public health systems face a choice between funding these medications and funding everything else—surgery, preventive care, routine treatment. Something has to give.

The pharmaceutical industry's defense is consistent: these prices reflect the enormous cost of research and development. Bringing a new drug to market, companies argue, requires years of work and billions in investment. The problem is that nobody can verify this claim. The actual costs of drug development remain secret. When governments negotiate prices with pharmaceutical companies, they do so in the dark, lacking the information needed to determine whether a price is fair or exploitative. The companies demand confidentiality not just for their asking price, but for the final negotiated price as well. The public sees a "notified price"—the official number—but not the discounts that were actually agreed to. The true cost to taxpayers remains hidden.

There is another layer to this opacity. Some pharmaceutical companies develop drugs using research funded by public money—government grants, university labs, tax-supported institutions. Yet when these companies set prices, they treat the entire development cost as their own investment, justifying premium pricing without acknowledging the public contribution. Patent law enables this arrangement. When a company receives a patent for a new drug, it gains exclusive rights to manufacture and sell that medication for twenty years. No competitor can enter the market. No generic version can be produced. Prices cannot fall through competition because competition is legally prohibited.

Spain's consumer advocates have proposed a five-point solution. They want transparency in the real prices governments pay for new drugs. They want disclosure of actual research and development costs, including any public funding involved. They want future drug prices set based on documented, verifiable costs rather than what companies claim the market will bear. They want Spain to reclaim the right to issue compulsory licenses—a legal mechanism that would allow the government to override a patent and permit another manufacturer to produce a critical drug if the patent holder's price is deemed unreasonable or a public health emergency exists. And they want patent law itself reformed to prevent the current system from continuing.

Compulsory licensing sounds straightforward in theory. If a patented drug is essential to public health and the price is unconscionable, the government can authorize another company to make and sell it domestically. In practice, Spain has never done this. No Spanish government has ever invoked compulsory licensing. There is no legal precedent, no established process. Challenging a pharmaceutical company in court means facing teams of highly specialized lawyers with resources to match. There is also a practical problem: Spain would need a manufacturer capable of producing the drug, and for complex biologics like gene therapies, such facilities are rare. Even if Spain granted a compulsory license, it could not import the drug from another country that had done the same—the European Union voluntarily surrendered that right years ago.

What remains clear is that the current system is unsustainable. Patients die or suffer permanent disability because they cannot afford drugs that exist. Health systems face bankruptcy if they try to fund these treatments for all who need them. The secrecy surrounding both development costs and final prices means there is no way to know whether the prices being charged are necessary or simply what the market will bear. The OCU is calling for public support, asking citizens to join a campaign against what it describes as abusive drug pricing. The question now is whether Spain, or any country, has the political will to challenge the pharmaceutical industry's pricing power—and whether the legal and manufacturing barriers to doing so can actually be overcome.